Northern Trust Corp Sells 18,733 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Northern Trust Corp reduced its stake in Amphastar Pharmaceuticals by 3.1%, selling 18,733 shares, and now holds approximately 1.25% of the company, valued at around $17.23 million.
• Institutional investors collectively own more than 65% of Amphastar Pharmaceuticals, with several firms significantly increasing their positions in recent months.
• Analysts have varied ratings on Amphastar Pharmaceuticals, with price targets ranging from $25.00 to $36.00, reflecting mixed sentiment about the stock's future performance.

Northern Trust Corp trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 3.1% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 594,437 shares of the company's stock after selling 18,733 shares during the period. Northern Trust Corp owned about 1.25% of Amphastar Pharmaceuticals worth $17,233,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMPH. Signaturefd LLC boosted its holdings in Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after acquiring an additional 520 shares during the last quarter. IFP Advisors Inc acquired a new position in Amphastar Pharmaceuticals during the 1st quarter valued at about $34,000. GF Fund Management CO. LTD. bought a new position in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $38,000. GAMMA Investing LLC grew its position in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after buying an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on AMPH shares. JPMorgan Chase & Co. restated a "neutral" rating and issued a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company decreased their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Needham & Company LLC upgraded Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price objective for the company in a report on Tuesday, August 12th. Finally, Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $31.60.

Amphastar Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:AMPH opened at $30.81 on Wednesday. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of 11.54 and a beta of 0.80. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $53.96. The company's fifty day simple moving average is $24.84 and its 200 day simple moving average is $25.74. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.